The idea may sound strange: a tobacco plant producing compounds like psilocybin or DMT. Sounds strange, right? You’ve probably never heard of it. But beyond the initial shock, what’s happening in the labs is less about “blending worlds” and more about something much deeper: changing the way these substances are produced and, eventually, the way they’re accessed.
A new study has succeeded in genetically modifying tobacco plants to produce several psychedelic compounds simultaneously. Specifically, researchers enabled them to produce five compounds: DMT, psilocin, psilocybin, bufotenin, and 5-MeO-DMT, all of which belong to the family of psychedelic tryptamines.
This is not an experiment meant for consumption, but rather a proof of concept that raises larger questions: what happens when these molecules are no longer dependent on natural sources?
To achieve this, the team reconstructed complete biosynthetic pathways in the plant using enzymes from different organisms, integrating multiple genes that allow natural precursors to be transformed into these complex molecules.
From Mushrooms to Biotechnology: Same Molecule, Different Origin
For decades, psychedelics such as psilocybin and DMT were associated with their natural sources: mushrooms, plants, and animal secretions. That connection is not only chemical: it’s also cultural. It involves ritual, territory, and tradition.
But from a scientific standpoint, there is one key point: the molecule is the same. This means that whether it comes from a mushroom, a laboratory synthesis, or now a modified plant, if the molecule is the same and properly isolated, its pharmacological properties do not depend on its origin, but on its chemical structure.
That’s where we start talking about biotechnology. Using plants as “living factories” allows compounds to be produced in a more controlled and potentially more cost-effective way, without relying on specific harvests or fragile ecosystems.
This isn’t the first time we’ve seen this. Compounds like insulin are already produced using modified organisms. In that sense, psychedelics could be following a similar path toward standardization.
Part of the interest in this approach also stems from ecological and ethical concerns, since some of these substances currently depend on limited or sensitive natural sources.
Why Tobacco?
The use of tobacco in this study has nothing to do with how it’s traditionally consumed. Tobacco is one of the most widely used plants in biotechnology for one simple reason: it grows quickly, is easy to genetically engineer, and produces large amounts of biomass. In technical terms, it is an ideal production platform.
In this case, the researchers used Nicotiana benthamiana, a tobacco species widely used in biotechnology for the reasons mentioned above. The genes were introduced into the leaves through a process known as agroinfiltration, a common technique in the field that allows new functions to be temporarily expressed in the plant.
The goal is not to smoke this plant or turn it into a new type of product. It is to use it as an efficient system for generating complex molecules that can then be isolated, purified, and studied.
Furthermore, this kind of development also allows for the development of modified variants of these compounds. In the study, the researchers succeeded in producing versions called halogenated analogs—in which hydrogen atoms are replaced by elements such as fluorine or chlorine—that may be more stable or more selective in how they act, something particularly relevant for pharmaceutical development.
The team also used artificial intelligence tools to optimize one of the key enzymes in the process, significantly increasing the yield of one of the compounds.
At a time when mental health research is expanding, having more accessible ways to study these compounds can accelerate the development of treatments.
Between Medicine and Culture: What’s Really at Stake
The real change isn’t about tobacco. It’s about the role psychedelics will play in the future.
On one hand, there is a clear shift toward integrating them into modern medicine: clinical trials, protocols, standardized doses. Within this framework, controlled production is key.
On the other hand, there is an entire cultural, spiritual, and communal dimension that cannot be replicated in a laboratory. For many people, the experience of these substances is not only pharmacological but also symbolic.
Biotechnology does not eliminate that dimension, but it does shift it away from the center. Even so, this is an early stage: the concentrations obtained were lower than those found in natural sources, so the system still requires optimization before large-scale production can be considered.
